MRK: FDA Approves KEYTRUDA
MRK's KEYTRUDA and KEYTRUDA QLEX are approved by the FDA for first-line treatment of PD-L1+ advanced triple-negative breast cancer
MRK FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS =10) Advanced Triple-Negative Breast Cancer (TNBC)